Health authorities of France have proclaimed their recommendation of taking the vaccine against the virus of human papillomavirus. This virus is responsible for most of the cervical cancer cases. The recommendation is also included for girls and teenagers from the age of 14, before their first sexual relations or even one year after.

With this, the Public Health Council of France (CSHPF) has recommended the vaccine for all women 15 to 23 years of age. The government of France will cover the cost of this vaccine for this age group.

Sources at the laboratory that produces this immunization have publicly expressed that this decision “confirms once again the exceptional importance of this vaccine for the health of women, and means the vaccine will protect more French women from cervical cancer and other diseases related to the human papillomavirus”. Also, the European Medicine Agency (EMEA) has approved this vaccine for a wider age range. According to what this institution published last September, this product has been authorized to be used between 9 and 26 years of age. The same criteria handled by its namesake in the USA, the Food and Drug Administration (FDA). However, each country can individually adapt these age recommendations for administering the vaccine, the product’s prices, budgeting, etc.

In fact, many countries have not yet approved the commercialization of the product, which is already available in 15 European countries, most of which have accelerated their local approval processes with the goal of incorporating the immunization against papillomavirus to the program of recommendations and coverage of each country. We should expect Latin American countries to also accelerate this process.

Source: LatinSalud.com with data from El Mundo, 20/03/2007

A controlled and constant physical activity can help you avoid being overweight.